Details of the Drug

General Information of Drug (ID: DMEHRAJ)

Drug Name
Rutin
Synonyms
RUTIN; 153-18-4; rutoside; Phytomelin; Quercetin 3-rutinoside; Birutan; Eldrin; Rutin trihydrate; Myrticolorin; Venoruton; Bioflavonoid; Paliuroside; Tanrutin; Osyritrin; Rutine; Rutozyd; 3-Rutinosyl quercetin; 3-Rhamnoglucosylquercetin; Quercetin 3-O-rutinoside; Rutosido; Rutosidum; Rutinum; Globularicitrin; Quercetin-3-rutinoside; Rutabion; Violaquercitrin; Globulariacitrin; Melin; Rutinic acid; Birutan Forte; Birutin; Quercetin rhamnoglucosine; Quercetin-3beta-rutinoside; UNII-5G06TVY3R7; Oxyritin; Rutosid; Ilixanthin; Rutinion acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 610.5
Topological Polar Surface Area (xlogp) -1.3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 10
Hydrogen Bond Acceptor Count (hbondacc) 16
Chemical Identifiers
Formula
C27H30O16
IUPAC Name
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
Canonical SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O
InChI
InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3/t8-,15+,17-,18+,20+,21-,22+,23+,26+,27-/m0/s1
InChIKey
IKGXIBQEEMLURG-NVPNHPEKSA-N
Cross-matching ID
PubChem CID
5280805
ChEBI ID
CHEBI:28527
CAS Number
153-18-4
DrugBank ID
DB01698
TTD ID
D09ALJ
VARIDT ID
DR01181
INTEDE ID
DR2149

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dihydrodiol dehydrogenase type I (AKR1C3) TT5ZWB6 AK1C3_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Alpha-L-rhamnosidase (lrA) DEC389G A0A385NJR4_9BACI Substrate [2]
Alpha-L-rhamnosidase (lrA) DEBI82Z A0A1V8Q7P3_9BIF Substrate [3]
Alpha-L-rhamnosidase (lrA) DE7BILX A0A1H8EBM0_9BACE Substrate [2]
Alpha-L-rhamnosidase (lrA) DE13AYF A0A179YH30_LACRH Substrate [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dihydrodiol dehydrogenase type I (AKR1C3) DTT AKR1C3 4.06E-01 1.39 0.74
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:95-100.
3 Metabolism of rutin and poncirin by human intestinal microbiota and cloning of their metabolizing alpha-L-rhamnosidase from Bifidobacterium dentium. J Microbiol Biotechnol. 2015 Jan;25(1):18-25.
4 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
5 Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004.
6 Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.